Esperion reports Q2 EPS 2c, consensus (16c)

Reports Q2 revenue $82.4M, consensus $63.05M. “Our Q2 results reflect the strength of our commercial execution and the growing adoption of our bempedoic acid therapies in cardiovascular disease prevention. With more than 15% sequential quarterly growth and 42% year-over-year quarterly growth in net U.S. product sales, we are delivering on our commitment to patients and shareholders alike,” stated CEO Sheldon Koenig. “The three recent ANDA settlements also demonstrate our commitment to protecting our intellectual property portfolio and reflect our belief in the strength of our patents. As we continue to expand access to these life-saving therapies through improved payer dynamics and prepare to launch our consumer television ad on connected TV, such as Hulu and NBC Sports, we remain focused on driving sustained revenue growth. In parallel, we are advancing our clinical pipeline and pursuing strategic portfolio expansion to shape the future of cardiovascular disease prevention worldwide. Importantly, we delivered our Q1 of operating income from ongoing business and expect our continued growth and achievements to support sustainable profitability beginning in Q1 of 2026. As we advance our growing leadership in cardiovascular diseases, we are proud to welcome Robert Hoffman and Craig Thompson, both seasoned executives with a wealth of commercial and operational expertise, to our Board of Directors”.